Table 1.
Differences in prognosis between patients with early versus late disease progression under different treatment regimens for FL patients
| Study | Number of patients |
Definition of POD24 | Treatment | POD24 rate | Pod24 OS | non-POD24 OS | HR/P |
|---|---|---|---|---|---|---|---|
| Casulo 11 | N=588 | POD24: POD occurred within 24 months after diagnosis | R-CHOP | 19% |
50% (5years) |
90% (5years) |
HR = 19.8 |
| Maurer23 | MER(N = 920) | EFS12/24: EFS24 was defined as EFS status 24 months from diagnosis. | WW(n = 326), R -mon(n = 111); immunochemotherapy (n = 349); Other therapies(n = 134) |
17% (EFS12) |
SMR = 13.2 (no EFS12:17.63) |
SMR = 0.37 (EFS12:0.74) |
- |
| Lyon(N = 412) | WW(n = 82), R -mon(n = 43); immunochemotherapy (n = 243); Other therapies(n = 44) |
18% (EFS12) |
SMR = 7.22 (EFS12:19.1) |
SMR = 0.90 (EFS12:1.03) |
- | ||
| Jurinovic18 | GLSG (n = 151) | POD24: POD occurred within 24 months after first-line treatment initiation | R-CHOP + IFN Maintenance | 17% |
41% (5years) |
91% (5years) |
HR = 9.72 |
| BCCA (n = 107) | R-CVP + R maintenance | 13% |
26% (5years) |
86% (5years) |
HR = 11.93 | ||
| Provencio24 | 1074 |
EFS12/EFS24: EFS12 /24indicates event-free survival at 12 months or 24 months |
CT with anthracyclines(n = 155 ) CT without anthracyclines (n = 96 ) With anthracyclines and rituximab (n = 610) Without anthracyclines and rituximab (n = 109 ) Rituximab monotherapy (n = 34) Surgery (n = 13) Observation(n = 18) |
- |
SMR = 8.42 (no EFS12:10.27) |
SMR = 1.3 (EFS12:1.75) |
- |
| Bachy16 | 1135 | EFS24: EFS24 was defined as EFS status 24 months from diagnosis | R-CHOP (n = 840); R-CVP(253); R-FCM(n = 42) | 25% |
63% (5years) |
92% (5years) |
P < 0.0001, |
| Freeman15 | N = 296 | POD24: POD occurred within 24 months after initiation of systemic therapy | BR | 13% |
38% (2 years) |
92% (2years) |
- |
| Sortais14 | N = 317 | POD24:POD or death from POD occurred within 24 months after diagnosis |
R-based(n = 259); radiotherapy alone (n = 9); anthracycline based regimens without R(n = 15); GR(n = 3); other regimens (n = 7) |
18.9% |
82 (5years) |
93.3% (5years) |
|
| Yoon20 | N = 324 | POD24: POD occurred within 24 months after treatment, | R-CVP (n = 152), | 16.4% | - | - | P = 0.192 |
| R-CHOP (n = 111), | 25.2% | ||||||
| BR ( n = 61) | 8.2% | ||||||
| Moccia38 | N = 318 | POD24: POD occurred within 24 months after chemoimmunotherapy |
R monotherapy(n = 244) R2(n = 74) |
27% |
69% (5years) |
92% (5years) |
P < 0·0001 |
|
59% (10 years) |
77% (10years) | ||||||
| Casulo17 | N = 5225 | - | Chemo(n = 2545); R-Chemo(n = 2410); R monotherapy(n = 270) | 29.3% |
71.2% (5years) |
93.6% (5years) |
- |
| Weibull22 | N = 948 | POD12: POD occurred within 12 months after first-line treatment initiation | R-chemo (R-CHOP (308), BR (105), R-CVP, R-FC (n = 519); R monotherapy (n = 156); other treatments (n = 156) | 28% |
34% (5years) |
78% (5years) |
- |
| P0D24 : POD occurred within 24 months after first-line treatment initiation |
46% (5years) |
82% (5years) |
- | ||||
| POD60: POD occurred within 60 months after first-line treatment initiation |
57% (5years) |
83% (5years) |
- |
FL: follicular lymphoma; POD = Progression of disease; event-free survival (EFS) = defined as time from diagnosis until relapse or progression, unplanned retreatment of lymphoma after initial management; The standardized mortality ratio (SMR) = the ratio of observed to expected deaths, based on the age and sex-matched general population; HR = hazard ratio; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; IFN = interfern ; R-CVP = rituximab, cyclophosphamide, vincristine, and prednisone; RFCM = rituximab plus fludarabine, cyclophosphamide and mitoxantrone; BR = bendamustine, Rituximab; R2 = Lenalidomide rituximab; GR = Obinutuzumab Lenalidomide; Chemo = chemotherapy ; CT = chemotherapy